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A long-standing challenge in malaria is the limited understanding of B cell immunity,
previously hampered by lack of tools to phenotype rare antigen-specific cells. Our aim
was to develop a method for identifying carbohydrate-specific B cells within lymphocyte
populations and to determine whether a candidate vaccine generated functional memory
B cells (MBCs) that reactivated upon challenge with Plasmodium (pRBCs). To this end,
a new flow cytometric probe was validated and used to determine the kinetics of B
cell activation against the candidate vaccine glycosylphosphatidylinositol conjugated
to Keyhole Limpet Haemocyanin (GPI-KLH). Additionally, immunized C57BL/6 mice
were rested (10 weeks) and challenged with pRBCs or GPI-KLH to assess memory B
cell recall against foreign antigen. We found that GPI-specific B cells were detectable
in GPI-KLH vaccinated mice, but not in Plasmodium-infected mice. Additionally, in
previously vaccinated mice GPI-specific IgG1 MBCs were reactivated against both
pRBCs and synthetic GPI-KLH, which resulted in increased serum levels of anti-GPI IgG
in both challenge approaches. Collectively our findings contribute to the understanding
of B cell immunity in malaria and have important clinical implications for inclusion of
carbohydrate conjugates in malaria vaccines.
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INTRODUCTION
The key criteria for long term immunity stems from the production of functional memory cells that
are capable of reactivating, and boosting, in response to antigenic challenge. Both HIV and malaria
are examples whereby protective natural immunity does not occur and there is accumulating
evidence of ineffectual or atypical memory B cells (MBCs), although their exact function in malaria
is still unknown (1–3). Furthermore, Plasmodium sp. have evolved mechanisms to evade the
immune system, such as allelic diversity and antigenic variation. To date there are three lines of
evidence to support the theory for B cell failure in malaria: (1) the observed partial acquisition of
humoral immunity during natural exposure (4), which only persists during constant exposure, (2)
the presence of atypical MBCs (4), and (3) the unexpected failure of the licensed RTS,S vaccine to
induce long-term protection (5).
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The only licensed malaria vaccine, RTS,S, specifically targets
the circumsporozoite protein (CSP), which is expressed on the
surface of the sporozoite prior to hepatocyte invasion (6), and
not during blood-stage infection. Despite initial promising field
trials, larger scale administration has resulted in a significant
public health issue, since vaccine efficacy has been reported
to be ∼30%, protection wanes quickly and antibody levels are
not maintained (5, 7). These observations are suggestive of B
cell memory failure, yet there is a lack of cellular evidence
to substantiate this possibly because of earlier methodological
constraints to directly study antigen-specific B cells, without the
need for pre-enrichment steps.
Recent application of tetramer probes in flow cytometry have
given insight into Plasmodium-specific B cell immunology (1,
8, 9), but knowledge surrounding B cell immunity in malaria
is still lagging behind other cellular immunology. In malaria,
tetramers have been used to either enrich for antigen-specific
cells (via anti-PE magnetic beads) (1), or in master mixes
containing other cell surface markers (9). These previous studies
target protein antigen, whereas our antigen of interest was a
small 9 k-Da carbohydrate. Therefore, we aimed to design an
alternative two-step staining flow cytometry protocol to identify
these carbohydrate-specific B cells.
Another identified challenge in malaria is if the efficacy of
the RTS,S can be improved with potential inclusion of other
antigenic targets, such as glycosylphosphatidylinositol (GPI).
GPI is expressed freely or functions as a membrane anchor
for numerous malaria proteins important for essential parasite
processes including facilitating red blood cell invasion (10).
Additionally GPI anchors CSP to the surface of the parasite, the
target protein in RTS,S. As a free moiety, GPI acts as a toxin
similar to LPS (11–14) and previous human (15, 16) and murine
(11) studies have demonstrated the importance of anti-GPI
antibodies in protection against severe disease or fatality. GPI is
structurally conserved across strains (17), species (18–21), and
expressed during all lifecycle stages, making it a favorable target.
We therefore sought in this study to address two questions.
The first to determine if we could develop a GPI specific probe
and, by doing so, track the kinetic response of B cells to a
novel carbohydrate-based vaccine (GPI) against Plasmodium.
The second was to assess if we could detect reactivation of GPI-
specific MBCs in GPI-vaccinated mice or Plasmodium-infected
mice in response to synthetic GPI or native GPI (blood-stage
infection). Our findings contribute to understanding the role B
cells play in clinical immunity.
MATERIALS AND METHODS
Vaccine Constructs
Synthetic glycosylphosphatidylinositol (GPI) was conjugated to
maleimide activated Keyhole Limpet Haemocyanin (KLH) using
2-iminothiolane and stored at −80◦C until use (GPI-KLH).
Abbreviations: BIO, biotin labelling; BSA, bovine serum albumin; GPI,
glycosylphosphatidylinositol; KLH, Keyhole Limpet Haemocyanin; MBC, memory
B cells; NP, Four-hydroxy-3-nitrophenyl acetyl-Osu; pRBCs, parasitized red
blood cells.
Four-hydroxy-3-nitrophenyl acetyl-Osu (NP-Osu) (Biosearch
Technologies, USA) was conjugated to KLH (Sigma-Aldrich,
USA;molar ratio between 13 and 20) according tomanufacturer’s
instructions and stored at−20◦C until use (NP-KLH).
Mice: Infections and Immunizations
For all experiments 6- to 8-week old inbred male and female
C57BL/6 mice were used and all procedures complied with
the Walter and Eliza Hall Institute Animal Ethics Committee
requirements. Infections and immunizations are outlined in
Supplementary Table 1. Mice were immunized with NP-KLH,
GPI-KLH, or KLH precipitated on 10% alum (Sigma-Aldrich,
USA) (Supplementary Table 1). Mice that were infected with
Plasmodium berghei by intraperitoneal (i.p.) injection were
given different numbers of parasitized red blood cells (pRBCs)
depending on the experiment (Supplementary Table 1) and
referred to as the group “Plasmodium.” All experimental mice
were drug-cured (Supplementary Table 1) (22).
Mice included in memory recall experiments, were rested a
minimum of 10 weeks and then injected (“challenged”) with
GPI-KLH i.p. or pRBCs i.p. to assess reactivation of MBCs
(Supplementary Table 1). A subset of GPI-KLH vaccinated mice
were included that were not injected at 10 weeks to represent a
baseline control. No more than 1 week prior to injection with
GPI-KLH or pRBCs, sera was collected via mandible bleeds.
Experiments were independently repeated 3 times and data
pooled for statistical analysis.
Preparation of Antigen-Specific Probes for
Flow Cytometry
The GPI probe was constructed by conjugating GPI to maleimide
activated bovine serum albumin (BSA) (ThermoScientific, USA)
and biotinylating with Biotin (BIO)-XX (Invitrogen, USA)
according to manufacturer’s instructions (ratio of 1:1). The
label is referred to as GPI-BSA-BIO. To determine optimum
ratio of biotin to Streptavidin-phycoerythrin (Strep-PE) (BD
Pharmingen, USA) for two-step staining in flow cytometry,
titrations were carried out on splenocytes from previously
vaccinated mice. To exclude background staining of BSA,
control reagents of BSA-BIO were prepared as above and
used in separate staining wells. To detect NP-specific B
cells, NIP-CAP-Osu (succinimide ester of 3-nitro-4-hydroxy-
5-iodophenylacetic acid spaced with caproic acid) (Biosearch
Technologies, USA) was conjugated to PE (20 µg: 1mg) (Life
Technologies, USA).
Flow Cytometry
Single cell suspensions from spleen or bone marrow were
prepared and 3 × 106 cells were added per well for staining.
For detection of GPI-specific B cells, a two-step staining method
was utilized. Gating strategies are included as supplementary
data (Supplementary Figure 1). The primarymaster-mix stained
for either GPI-BSA-BIO or background staining of BSA-BIO.
There was no detectable non-specific staining with BSA-BIO (see
Supplementary Figure 2). Following incubation, splenocytes
were washed and re-suspended in secondary mastermixes.
The following fluorochrome-conjugated monoclonal antibodies
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were used to stain B cells in the secondary mastermix:
Pacific Blue (PB) anti-CD19 (clone 1D3, Ebioscience, USA),
allophycocyanin (APC) anti-Immunoglobulin G1 (IgG1) (clone
X56), PECy7 anti-CD95 (clone Jo2), fluorescein isothiocyanate
(FITC), anti-CD38 (clone Ab90). IgD+ and/or Gr1+ cells
were determined by Alexa 680 (A680) anti-IgD (clone 1126C)
and A680 anti-Gr1 (clone 8C5) and excluded using a dump
channel. This was to exclude naïve IgD positive B cells
and granulocytes. For plasma cells, there was a one-step
staining process with the mastermix containing PECy7 anti-
B220 (clone RA3-6B2), and PE anti-CD138 (clone 281-2) (BD
biosciences, USA).
For all staining, dead cells were excluded using live/dead
fixable yellow dead cell staining kits (Life technologies, USA).
Antigen specificity was determined using GPI-BSA-BIO/Strep-
PE or NP-PE. Fluorescence Minus One (FMO) controls were
included to allow accurate gating. Sample analysis was performed
on a FortessaX20 flow cytometer and Cell Quest software
packages (BD biosciences, USA). A minimum of 500 000 events
was acquired. Data were analyzed using FlowJo Version 9.9.6
software (TreeStar).
ELISA and ELISPOTS
Antibody secreting cells (ASCs) were assessed using ELISPOTs.
Spleen (1 × 106 cells and 0.5 × 106 cells) or bone marrow
cells (1 × 106 cells and 0.5 × 106 cells) were added to 96-
well cellulose ester membrane plates (MAHAS4510; Millipore)
coated with NP13-BSA (10 µg/mL) or GPI8-BSA (10 µg/mL)
and incubated at 37◦C and 5% CO2 for 8 h. To measure total
IgG, wells were coated with sheep anti-mouse IgG (#AC111;
Millipore) at 10 µg/mL. Concentration of cells to measure total
IgG ASCs were 1 × 105, 0.5 × 105, and 0.1 × 105 per well. Anti-
NP IgG, anti-GPI IgG or total IgG ASCs were detected using
goat anti-mouse IgG conjugated to ALP (#3310-4; MabTek)
and visualized using the BCIP/NBT system (# 50-81-00; KPL,
USA). Spots were counted using an automated reader (AID
ELISPOT Reader System, software version 7) and calculated
as ASCs/1× 106.
Blood was collected and serum separated at times indicated
for ELISA. 96-well MaxiSorp plates were coated with GPI-
BSA (10 ng/well) and titrated serum was incubated for at
least 24 h at 4◦C. Anti-GPI IgG was detected using goat anti-
mouse IgG-HRP (SouthernBiotech) and visualized with 3,3′,5,5′-
tetramethylbenzidine (TMB) substrate (#T8665, Sigma Aldrich).
Antibody concentrations were quantitated using standard curves
of known IgG protein concentrations.
Statistical Analysis
Median values were compared by Mann-Whitney or Wilcoxon
matched-pairs signed rank test where appropriate, using Prism
version 7 software (GraphPad). Statistical significance comparing
more than two groups in an analysis was determined using
Kruskal-Wallis followed by Dunn’s multiple comparison test
as indicated.
RESULTS
Synthetic GPI-KLH Vaccination Induced
Activation of B Cells Including
Class-Switched Antigen-Specific and
Memory B Cells
Previous studies have shown the importance of antibodies
against GPI for protection against severe disease (15, 16) and
GPI-KLH vaccination protects against systemic inflammation
and fatality in mice (11). However, B cell responses to GPI
have not yet been characterized in humans or mice, either to
infection or GPI-KLH vaccination, and few studies describe
the antigen-specific B cell response to malaria in mouse
experimental systems. We sought to assess whether B cells
proliferated in response to standard GPI-KLH vaccination or
native GPI expressed by Plasmodium, and determine which B
cell subset populations were involved. Mice were vaccinated
twice with NP-KLH, GPI-KLH, or KLH alone according to
standard immunization protocols or exposed to pRBC twice
(referred to as Plasmodium) (Supplementary Table 1) and
euthanized at days 21 or 46. NP-KLH was used as a reference
antigen since B cell kinetics has been well-documented (23).
Mice vaccinated with KLH alone were included as controls
to ensure the flow cytometry probe was GPI-specific and
not cross-reacting with KLH-specific B cells. B cells were
measured using flow cytometry to quantify subsets of B
cells (Figure 1).
B cell activation in response to vaccination with GPI-
KLH was similar to NP-KLH at day 21 (Figures 1A–E). This
was determined by comparable numbers of cells that had
undergone class-switching to IgG1 (Figure 1A), presence of
antigen-specific IgG1 MBCs (Figure 1B), number of germinal
center (GC) B cells (Figure 1C), antigen-specific IgG1 B
cells within the GC (Figure 1D), and the number of plasma
cells (PCs) (Figure 1E). Splenocyte counts of activated and
antigen-specific IgD−GPI+IgG1+ B cells from GPI-KLH
vaccinated mice were significantly higher than the control
groups (naïve, KLH) and Plasmodium mice, both overall and
within the GC (Figures 1A,D). Furthermore, assessment of
IgD−GPI+IgG1+CD38+ B cells, whereby CD38+ represents
murine MBCs (24) showed that these cells were significantly
higher in GPI-KLH vaccinated mice compared to naïve, KLH, or
the Plasmodium experimental groups. Overall, Plasmodiummice
had significantly higher numbers of GC B cells than naïve and
NP-KLH mice (Figure 1C), but these were not specific for GPI
(Figure 1D). These Plasmodium mice also had a significantly
expanded population of PCs at day 21 when compared to
naïve mice (Figure 1E). See Supplementary Figure 2 for
representative flow plots.
The capacity of PCs to secrete antigen-specific IgG was
measured from isolated splenocytes (day 21) or isolated
lymphocytes from bone marrow (Day 46) in all experimental
groups (naïve, KLH, NP-KLH, GPI-KLH, and Plasmodium;
Figure 2). Significantly higher counts of anti-GPI IgG antibody
secreting cells (ASCs) were observed from the spleens and
bone marrow of GPI-KLH vaccinated mice than Plasmodium
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FIGURE 1 | Synthetic GPI-KLH vaccination induced B cell activation. Mice were vaccinated and boosted with NP-KLH (n = 5), GPI-KLH (n = 5), or KLH alone (n = 5)
(20 µg/µL) or infected twice with 106 pRBCs then 104 pRBCs (Plasmodium, n = 5). Naïve mice (n = 5) were included as a baseline. At day 21, activated B cell
populations were analyzed by flow cytometry and the number of cells per spleen for (A) antigen-specific IgG1 B cells, (B) antigen-specific IgG1 memory B cells
(MBCs), (C) germinal center (GC) B cells, (D) antigen-specific IgG1 GC B cells, and (E) Plasma cells (PCs) were determined for each mouse. Pooled data from all mice
are represented as median ± 95%CI. Data was analyzed using the non-parametric Kruskal-Wallis test and differences determined by Dunn’s multiple comparisons
test. Significance was determined at P < 0.05. NS not significant, #naïve and KLH-immunized mice were significantly different to both groups of NP-KLH and
GPI-KLH mice P < 0.05, ##Plasmodium mice were significantly different to GPI-KLH mice P < 0.01, *P < 0.05, **P < 0.01, ***P < 0.001.
or control mice (naïve, KLH) which was similar in numbers to
anti-NP IgG ASCs in the NP-KLH vaccinated mice (Figure 2).
Challenge With Synthetic GPI-KLH or
pRBCs Induced Rapid Activation of
GPI-Specific MBCs in Previously
GPI-Vaccinated Mice
For GPI to be an effective vaccine target, GPI-specific
MBCs must be functional to facilitate long-term immunity.
Functionality can be characterized by the ability to rapidly
expand upon antigenic challenge as measured by antigen-
specific B cells and production of ASCs (25). To investigate
recall of GPI-specific MBCs in response to antigenic challenge,
mice that had been vaccinated with GPI-KLH were rested
for 10 weeks following vaccination to enter the quiescent
memory phase (1). Mice were either left unchallenged
(referred to as baseline) or challenged with (i) synthetic
GPI-KLH or (ii) pRBCs (Figure 3I). Five days later splenocytes
were isolated to assess antigen specific B cells using flow
cytometry (Figures 3II,III).
Absolute numbers of GPI-specific B cells reactivated
significantly in mice following challenge with synthetic GPI-
KLH, compared to baseline mice at day 5 (Figures 3IIIA–C).
Non-specific depression of proliferation of lymphocytes by
malaria infection has been previously noted (26, 27) and
therefore, as expected, P. berghei infection induced cellular
depression (Figures 3IIIA,B). Cellular frequencies in this
instance were an indication of cellular reactivation in response
to infection as there was a significant increase in GPI-specific B
cells (ratio of all activated B cells) when compared to baseline
(Figure 3IIIC).
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FIGURE 2 | Synthetic GPI-KLH vaccination induced antigen-specific IgG antibody secreting cells (ASCs) in spleen (day 21) and bone marrow (day 46). Mice were
vaccinated and boosted with NP-KLH (n = 5), GPI-KLH (n = 5), or KLH alone (n = 5) (20 µg/µL) or infected twice with 106 pRBCs then 104 pRBCs (Plasmodium,
n = 5). Naïve mice (n = 5) were included as a baseline. Splenocytes (open circles, day 21), or lymphocytes (filled squares, day 46) were isolated from the spleen and
bone marrow, respectively, and cell counts of antibody secreting cells (ASCs) were quantitated. Pooled data from all mice are represented as median ± 95%-CI. Data
was analyzed using the non-parametric Kruskal-Wallis test and differences determined by Dunn’s multiple comparisons test. Significance was determined at P < 0.05.
*Statistically higher than naïve, KLH-vaccinated, or Plasmodium mice at both day 21 and 46. P < 0.05.
To establish whether these GPI specific B cells were in fact
originating from reactivation of MBCs rather than activation
of naïve B cells against foreign antigen, we also challenged
naïve mice with synthetic GPI-KLH or pRBCs and quantified
GPI-specific B cells (Figure 4; Supplementary Figure 3).
When challenged with synthetic GPI-KLH or pRBCs, there
was no evidence of GPI specific B cells or GPI+IgG1+ B
cells in naïve mice (Figures 4IIA,B). When challenged with
synthetic GPI-KLH, PC production in the spleen was lower
in naïve mice than GPI-KLH vaccinated mice, but this
difference was not statistically significant (Figure 4IIC).
Similarly, when infected with pRBCs, PC counts from
naïve mice were not different from GPI-KLH vaccinated
mice (Figure 4IIC).
Since we showed that infection with pRBCs, and thus
parasite GPI, induced GPI specific MBC activation in previously
vaccinated mice compared to baseline (Figure 3IIIC) and
naïve mice (Figures 4IIA,B) we sought to investigate if
Plasmodium mice underwent GPI-specific MBC reactivation
when challenged with synthetic GPI-KLH or a third infection
with pRBCs (Figures 4IIIA,B). It is conceivable that B cells
could have generated GPI-specific memory during the initial
infections in the Plasmodium group against native parasite
GPI (28). However, we observed that GPI-specific B cell
counts, including GPI+IgG1+ B cells and GPI+IgG1+ GC
B cells, were significantly higher in vaccinated mice when
challenged with GPI-KLH or pRBCs than Plasmodium mice
(Figures 4IIA,B). There were no significant differences between
Plasmodium or naïve mice for antigen specific cell counts.
Furthermore, when challenged with GPI-KLH, vaccinated mice
generated significantly higher numbers of PCs than Plasmodium
mice (Figure 4IIC). On the contrary, when both groups
were challenged with pRBCs, only the Plasmodium mice had
significantly higher PC counts than both GPI-KLH vaccinated
mice and naïve mice (Figure 4IIC). This was further investigated
using ELISPOTs.
MBC Are Functional ASCs in
GPI-Vaccinated Mice and Plasmodium
Mice When Challenged With GPI-KLH or
pRBCs
MBC functionality can be measured by rapid differentiation
into ASCs. From the flow cytometry analysis, we observed
high frequencies of PCs in GPI-KLH vaccinated mice when
challenged with GPI-KLH, but these counts were only significant
compared to Plasmodium mice (Figure 4IIC). Additionally,
when challenged with pRBCs, Plasmodium mice had a
considerable population of PCs which was significantly higher
than both GPI-KLH vaccinated and naïve mice (Figure 4IIC).
From these observations, we sought to determine in each
experimental group if spleen PCs were secreting the isotype IgG
and whether these were GPI-specific (Figure 5). To this end, we
used ELISPOTS coated with GPI-BSA or sheep anti-mouse total
IgG to detect anti-GPI IgG ASCs or total IgG ASCs, respectively.
GPI-vaccinated mice had significantly higher counts for
anti-GPI IgG ASCs than both Plasmodium and naïve mice
when challenged with either GPI-KLH or pRBCs (Figure 5A).
Plasmodium mice had significantly higher total IgG ASCs than
both naïve and GPI-KLH vaccinated mice when challenged with
a third dose of pRBCs (Figure 5B).
To investigate if ASCs also secreted significant quantities of
anti-GPI IgG into the blood in vivo, sera samples taken from
cardiac bleeds at day 5 (post-challenge) were analyzed for anti-
GPI IgG using ELISAs (Figure 6A). Anti-GPI IgG measured in
the sera of GPI-KLH vaccinated mice was significantly higher
compared to naïve and Plasmodium mice after challenge with
either GPI-KLH or pRBCs (Figure 6A). To determine if this
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FIGURE 3 | Challenge with (i) synthetic GPI-KLH or (ii) pRBCs induced rapid recall/activation of GPI-specific MBCs in previously GPI-vaccinated mice compared to
baseline memory mice. Panel (I) Mice were vaccinated and boosted with GPI-KLH (n = 30). After resting for a minimum of 10 weeks when the B cells are considered
to be in the quiescent memory phase, mice were injected with (i) GPI-KLH i.p. (n = 12) or (ii) 1 × 105 pRBCs i.p. (n = 12) or nothing (baseline; n = 6) to assess
reactivation of MBCs. Panel (II) outlines FACS plots. Panel (III) is the analysis of B cell populations for the number of cells per spleen for (A) GPI-specific B cells, (B)
GPI-specific IgG1 B cells, and (C) calculated cell frequencies of GPI-specific B cells as a proportion of all activated B cells. Experiments were reproduced
independently thrice. Pooled data from all mice from all 3 experiments are represented as median ± 95%-CI. Data was analyzed using the non-parametric
Mann-Whitney test and significance was determined at P < 0.05. *P < 0.05, **P < 0.01, NS not significant.
was a boosting effect in response to challenge, or residual high
levels induced from earlier vaccination, sera samples from GPI-
KLH vaccinated mice were taken up to a week prior to challenge
(pre-challenge) and compared to the post-challenge titer using
pairedWilcoxon tests (Figure 6B). Synthetic GPI-KLH challenge
produced a significant boosting of anti-GPI IgG titers and,
although pRBC challenge also boosted titers of anti-GPI IgG, this
was not significant (Figure 6B). Little detectable anti-GPI IgG
was measured for naïve or Plasmodium mice.
DISCUSSION
Activation of antigen-specific B cells in response to foreign
antigen, and the subsequent affinity maturation, class-switching,
MBC production, long-lived PCs and antibody production
play an integral role in adaptive humoral immunity (29).
Carbohydrate antigens are weakly immunogenic and classified
as Thymus-Independent (TI) type I or II (30). In order to
generate the above favorable Thymus Dependent (TD) response,
carbohydrates can bemanipulated in different vaccine regimes by
the use of adjuvants or conjugation to other immunodominant
protein carriers. Historically carbohydrate-conjugated vaccines
have been successful for reducing incidence of diseases and
the advancement in glycobiology has allowed carbohydrate-
based vaccines to gain momentum for their potentially broad
application in other infectious diseases including malaria
(11, 31). Our study has for the first time been able to
detect carbohydrate-malaria-specific B cells and the subsequent
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FIGURE 4 | Challenge with synthetic GPI-KLH or pRBCs induced rapid activation of GPI-specific MBCs in previously GPI-vaccinated mice, whilst Plasmodium mice
do not generate GPI-specific MBC. Mice were vaccinated and boosted with GPI-KLH (n = 24) or infected twice with pRBCs i.p. (n = 24, referred to as Plasmodium
mice). Naïve mice were included as a control group (n = 24). After resting for a minimum of 10 weeks, mice were injected with GPI-KLH i.p. (closed circles; n = 12
from each group) or 1 × 105 pRBCs i.p. (open squares; n = 12 from each group) to assess reactivation of MBCs at day 5. Panel (I) outlines experimental design. Panel
(II) is the analysis of activated B cell populations for the number of cells per spleen for (A) GPI-specific B cells, (B) GPI-specific IgG1 B cells, and, (C) Plasma Cells at
day 5. Experiments were reproduced independently thrice. Pooled data from all mice from all 3 experiments are represented as median ± 95%-CI. Data was analyzed
using the non-parametric Kruskal-Wallis test and differences determined by Dunn’s multiple comparisons test. Significance was determined at P < 0.05. (A,B) #when
challenged with GPI-KLH or pRBCs, the initial experimental groups of naïve mice and Plasmodium mice were significantly lower than GPI-KLH mice (P < 0.05). (C)
#when challenged with GPI-KLH the initial experimental group of Plasmodium mice was significantly lower than the GPI-KLH mice (P < 0.05); ##when challenged
with pRBCs, the initial experimental groups of naïve and GPI-KLH mice were significantly lower than Plasmodium mice for plasma cell production (P < 0.05).
reactivation and boosting of these functional MBCs in response
to both synthetic carbohydrate antigen and Plasmodium
blood-stage infection. Importantly, this was achieved through
developing a GPI-BSA-BIO probe, which enabled phenotypic
assessment of activated carbohydrate-specific B cells following
vaccination and re-activation in response to infection with
minimal in vitromanipulation.
TI-I and II responses differ via their mechanism of B cell
activation. TI-I antigens are further classified based on antigen
concentration. In high concentrations, foreign antigen binding
is via Toll-Like Receptors (TLRs) inducing mitogenic non-
specific polyclonal activation of B cells, thereby precluding
Ig epitope recognition and are often deleterious to the
host (30). As the concentration of these antigens reduce,
cross-linking of the Ig can occur via epitope recognition
enabling antigen-specific activation of B cells and formation
of functional MBCs. However, there MBCs are predominantly
short-lived IgM MBCs (32). A well-characterized TI-I antigen
is LPS and different doses activate B cells via these different
pathways (33). Since GPI behaves like LPS, it is feasible that
the biological mechanism of natural infection with native
GPI would also be similar. Therefore, the proposed vaccine
construct GPI-KLH has been conjugated to a carrier protein
to favor TD responses and generation of class-switched
functional MBCs.
The hapten NP has successfully been used to track antigen-
specific B cell responses. As such, we employed the same NP-
KLH system as a means to compare the responses of our
GPI-KLH vaccine. We found that B cells were activated in
response to GPI-KLH similarly to the standard hapten NP-KLH.
Vaccination elicited class-switching, antigen specificity, long-
lived PCs, sera titers of anti-GPI IgG, and IgG1+GPI+ MBCs.
This is indicative of a TD response and favorable characteristics
of humoral-based vaccines (29). However, in addition to eliciting
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FIGURE 5 | MBC differentiate into ASCs and produce antibodies in vaccinated mice when given GPI-KLH or pRBCs, and in Plasmodium mice when given a third
dose of pRBCs. Mice were vaccinated and boosted with GPI-KLH (n = 24) or infected twice with pRBCs i.p. (n = 24, referred to as Plasmodium mice). Naïve mice
were included as a control group (n = 24). After resting for a minimum of 10 weeks, mice were injected with GPI-KLH i.p. (n = 12 from each group) or 1 × 105 pRBCs
i.p. (n = 12 from each group) to assess reactivation of MBCs and differentiation into ASCs at day 5 using ELISPOTs. (A) Denotes the proportion of GPI-specific
ASCs/1 × 106 cells for challenge with synthetic GPI (closed circle) or pRBCs (open square). (B) Denotes the proportion of total ASCs/1 × 106 cells for challenge with
synthetic GPI (closed circle) or pRBCs (open square). Pooled data from all experimental mice are represented as median ± 95%-CI. Data was analyzed using the
non-parametric Kruskal-Wallis test and differences determined by Dunn’s multiple comparisons test. Significance was determined at P < 0.05. #GPI-specific ASCs in
spleens of GPI-vaccinated mice statistically higher than naïve and Plasmodium mice when challenged with both GPI or pRBCs (P < 0.05); ##total IgG in spleens of
Plasmodium mice statistically higher than naïve and GPI mice when challenged with pRBCs (P < 0.01).
FIGURE 6 | Higher titers of anti-GPI IgG at day 5 in GPI-KLH mice following injection with synthetic GPI-KLH or pRBC compared to naïve or Plasmodium mice. Mice
were vaccinated and boosted with GPI-KLH (n = 24) or infected twice with pRBCs i.p. (n = 24). Naïve mice were included as a control (n = 24). Mice were rested for
10 weeks. Mice were subsequently challenged with GPI-KLH i.p. or 1 × 105 pRBCs i.p. and post-challenge sera collected from a cardiac bleed at day 5. (A) Day 5
titers were compared among groups to measure titers of anti-GPI IgG in response to GPI-KLH (filled bars; n = 12 from each group) or pRBCs (checked bars; n = 12
from each group). Pooled data from all experimental mice was analyzed using the non-parametric Kruskal-Wallis test and differences determined by Dunn’s multiple
comparisons test. Significance was determined at P < 0.05. (B) In the GPI-KLH vaccinated group, sera samples were taken up to 7 days prior to challenge with
GPI-KLH or pRBCs and titers measured (closed circles; pre-challenge). These titers were pair-matched to day 5 post-challenge titers (open circles; post-challenge)
using the Paired Wilcoxon test to measure potential boosting of anti-GPI IgG in response to GPI-KLH or pRBCs. Significance was determined at P < 0.05. Data are
represented as median ± 95%-CI. #GPI-KLH vaccinated mice statistically higher than naïve mice and Plasmodium mice (P < 0.001). ##significant increase in
anti-GPI IgG comparing pre- and post-challenge sera titers (P < 0.05).
an appropriate response, the reactivation of antigen-specific
MBCs upon subsequent antigenic challenge is the ultimate goal
for clinicians. This is especially important in light of poor
immunological responsiveness to RTS,S.
We used a similar protocol to Krishnamurty et al. (1) to
show that GPI-specific MBCs generated in response to GPI-
KLH vaccination were reactivated upon synthetic GPI-KLH
challenge or infection with Plasmodium (pRBCs). Synthetic GPI-
KLH induced significant cellular increases in GPI-specific B cells,
anti-GPI IgG ASCs, and boosting of sera titers. This response
was indicative of memory recall, since naïve mice did not have
a detectable antigen-specific response at this time. Boosting
and reactivation of MBCs agrees with other carbohydrate
immunizations (34, 35).
When challenged with P. berghei, there was a significantly
higher % of GPI-specific B cells complementing a significant
generation of anti-GPI secreting PCs in the spleen. Furthermore,
when these infected vaccinated mice were compared to infected
naïve mice or previously infected mice (Plasmodium mice)
challenged with pRBCs for the third time, there was a
significantly higher post-challenge sera titer of anti-GPI IgG.
Although it is not possible to conclude from this study what
underlying cellular processes involved in this recall response in
vaccinated mice with native GPI are, it could be speculated that
native GPI during infection is binding via epitope recognition
on surface Ig on the functional MBCs that were formed during
initial vaccination, thereby allowing their controlled expansion
and boosting. The mechanisms behind this recall activation and
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how this differs from reactivation using synthetic GPI-KLH
challenge remains to be defined. Nevertheless, these observations
have significant clinical implications creating a system whereby
natural infection will continue to boost and clonally expand
MBCs in vaccinated mice.
In contrast, MBC reactivation in previously infected mice
challenged with either synthetic GPI-KLH or a third infection
did not induce GPI-specific responses. In the previous infections
in these Plasmodium mice, the higher concentrations of native
GPI has likely inhibited the antigen-specific activation of B cells
through mitogenic polyclonal TLR activation. Therefore, it is not
surprising that we cannot detect GPI-specific B cells in response
to challenge with either synthetic GPI nor a third infection
with native GPI. Another explanation could be activation of
the enzyme indoleamine 2,3 dioxygenase which occurs during
malaria infection (27). This enzyme is important for tryptophan
metabolism and has been shown to inhibit B cell responses
to TI antigens (26). Despite which mechanism is responsible,
these findings agree with Keitany et al. (8) who also found that
antigenic challenge in previously infected mice failed to induce
antigen-specific MBC reactivation.
We have shown for the first time that GPI-specific MBC
recall can be observed in vaccinated mice in response to
infection with Plasmodium. The extent to which findings in the
experimental mouse model should be extrapolated to human
disease should be viewed with caution. Future studies need to
establish whether affinity matured, isotype switched MBCs can
be generated during a GPI-KLH vaccine regime administered to
a previously Plasmodium infected mouse in the quiescent phase
when parasites are cleared. This would ensure that functional
MBCs can be generated after previous infection, which would
mimic vaccination in endemic regions. Future studies may
also investigate the kinetic response of GPI B cell reactivation
following pRBC challenge at later time points in order to track
secondary GC formation following antigen re-exposure, as well
as the protective efficacy of vaccination.
We have also established that natural infection with
Plasmodium is unlikely to generate efficient GPI-specific
MBCs, potentially because of the mechanism by which
GPI drives activation and differentiation of B cells as a
TI-I antigen. By utilizing the glycoconjugate in a vaccine
formulation, and altering themechanism of antigen presentation,
vaccinated mice do generate functional GPI-specific MBCs
capable of recall and boosting upon natural infection. Our
research raises interesting biological questions and observations
about the potential mechanisms by which Plasmodium drives
differentiation and activation of B cells, and the phenomenon
of inefficient or partial immunity as a result of this, through
use of different activation signaling pathways within naïve B
cells. It has become essential to understand and learn the
mechanisms contributing to MBC failure in natural infection
in order to appropriately target next generational malaria
vaccines. Our research has significant clinical implications for
including glycan targets in the malaria elimination agenda,
either as a complement to RTS,S or when pursuing new
vaccine formulations.
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Supplementary Figure 1 | Flow cytometry gating strategy. This is the flow
cytometry gating strategy using an example of a spleen isolated from a
GPI-immunized mouse at day 14.
Supplementary Figure 2 | Representative plots for experimental groups; one
mouse from each group.
Supplementary Figure 3 | Challenge with synthetic GPI-KLH or pRBCs induced
rapid activation of GPI-specific MBCs in previously GPI-vaccinated mice, whilst
Plasmodium mice do not generate GPI-specific MBC. Mice were vaccinated and
boosted with GPI-KLH (n = 24) or infected twice with pRBCs i.p. (n = 24, referred
to as Plasmodium mice). Naïve mice were included as a control group (n = 24).
After resting for a minimum of 10 weeks, mice were injected with GPI-KLH i.p. or
1 × 105 pRBCs i.p. to assess reactivation of MBCs at day 5. The supplementary
figure outlines FACS plots.
Supplementary Table 1 | Vaccination/Infection protocol for assessing B cell
activation kinetics and memory B cell recall.
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